Fuller & Thaler Asset Management, Inc. Alaunos Therapeutics, Inc. Transaction History

Fuller & Thaler Asset Management, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.41 - $1.24 $324,305 - $980,827	-790,990 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$0.62 - $1.17 $1,922 - $3,627	3,100 Added 0.39%	790,990 $516,000
Q4 2021 Feb 09, 2022	BUY	$1.09 - $1.89 $858,800 - $1.49 Million	787,890 New	787,890 $859,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $424M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Fuller & Thaler Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Fuller & Thaler Asset Management, Inc. with notifications on news.